Australia's most trusted
source of pharma news
Friday, 26 April 2024
Posted 12 May 2022 AM
Bayer has dropped its appeal to a decision that invalidated its patent extension for oral contraceptive Yaz, a move which threatens a number of pharmaceutical patent extensions.
The Full Federal Court has ruled against pharmaceutical companies on a number of appeals concerning patent term extensions (PTEs), and with no appeal to the High Court those decisions seem final.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.